Hypolipidaemic and anti-inflammatory effects of fixed dose combination of atorvastatin plus ezetimibe in Indian patients with dyslipidaemia

Share this Article

Singapore Med J 2013; 54(2): 90-95; http://dx.doi.org/10.11622/smedj.2013031

Padhy BM, Yadav R, Gupta YK
Correspondence: Dr Biswa Mohan Padhy, drbisu7@gmail.com

ABSTRACT
Introduction We aimed to assess the efficacy of fixed dose combination of atorvastatin plus ezetimibe in Indian patients with dyslipidaemia.
Methods A double-blind study was conducted to assess the effect of fixed dose combination of ezetimibe 10 mg plus atorvastatin 10 mg on lipid profile, oxidised low-density lipoprotein (ox-LDL), high-sensitivity C-reactive protein (hsCRP) and soluble intercellular cell adhesion molecule (sICAM) in dyslipidaemic patients with or at high risk of coronary artery disease, and compare it with atorvastatin 10 mg monotherapy. 30 patients were randomised to receive ezetimibe plus atorvastatin or atorvastatin once daily for four weeks.
Results Of the 30 patients, 10 men and 5 women (mean age 54.3 ± 1.6 years) received ezetimibe plus atorvastatin, while 13 men and 2 women (mean age 53.7 ± 2.8 years) received only atorvastatin. The combination treatment significantly reduced total cholesterol (percentage treatment difference −14.4 ± 6.5, 95% confidence interval [CI] −1.0 to −27.7; p = 0.041) and LDL cholesterol (LDL-C; percentage treatment difference −19.9 ± 6.1, 95% CI −7.4 to −32.4; p = 0.003) compared to atorvastatin monotherapy. 13 patients on combination treament achieved the National Cholesterol Education Program target for LDL-C as compared to 9 patients on atorvastatin monotherapy (p = 0.032). Significant reductions in very low-density lipoprotein cholesterol, triglyceride, ox-LDL and sICAM were observed with combination treatment compared to atorvastatin monotherapy. However, no significant change was seen in high-density lipoprotein cholesterol or hsCRP levels between the two groups.
Conclusion Combination treatment with atorvastatin and ezetimibe had relatively better lipid-lowering and anti-inflammatory efficacy than atorvastatin monotherapy.

Keywords: atorvastatin, ezetimibe, high sensitivity C-reactive protein, intercellular cell adhesion molecule
Singapore Med J 2013; 54(2): 90–95; http://dx.doi.org/10.11622/smedj.2013031

REFERENCES

1. Sharma M, Ganguly NK. Premature coronary artery disease in Indians and its associated risk factors. Vasc Health Risk Manag 2005; 1:217-25.

2. Goyal A, Yusuf S. The burden of cardiovascular disease in the Indian subcontinent. Indian J Med Res 2006; 124:235-44.

3. Gupta R, Gupta VP, Sarna M, et al. Prevalence of coronary heart disease and risk factors in an urban Indian population: Jaipur Heart Watch-2. Indian Heart J 2002; 54:59-66.

4. Srinath Reddy K, Shah B, Varghese C, Ramadoss A. Responding to the threat of chronic diseases in India. Lancet 2005; 366:1744-9. http://dx.doi.org/10.1016/S0140-6736(05)67343-6

5. Nixon JV. Who should receive a statin drug to lower cardiovascular risk? Does the drug and the dose of the drug matter? Vasc Health Risk Manag 2006; 2:441-6. http://dx.doi.org/10.2147/vhrm.2006.2.4.441

6. Rutishauser J. The role of statins in clinical medicine-LDL—cholesterol lowering and beyond. Swiss Med Wkly 2006; 136:41-9.

7. Davignon J, Leiter LA. Ongoing clinical trials of the pleiotropic effects of statins. Vasc Health Risk Manag 2005; 1:29-40. http://dx.doi.org/10.2147/vhrm.1.1.29.58937

8. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002; 110:285-8.

9. Miida T, Hirayama S, Nakamura Y. Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia. J Atheroscler Thromb 2004; 11:253-64. http://dx.doi.org/10.5551/jat.11.253

10 .Hamilton-Craig I, Kostner K, Colquhoun D, Woodhouse S. Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia. Vasc Health Risk Manag 2010; 6:1023-37. http://dx.doi.org/10.2147/VHRM.S13496

11. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44:720-32. http://dx.doi.org/10.1016/j.jacc.2004.07.001

12. Backes JM, Gibson CA, Howard PA. Optimal lipid modification: the rationale for combination therapy. Vasc Health Risk Manag 2005; 1:317-31. http://dx.doi.org/10.2147/vhrm.2005.1.4.317

13. Neal RC, Jones PH. Complementary therapy to target LDL cholesterol: the role of the ezetimibe/simvastatin combination. Vasc Health Risk Manag 2006; 2:31-8. http://dx.doi.org/10.2147/vhrm.2006.2.1.31

14. Al Badarin FJ, Kullo IJ, Kopecky SL, Thomas RJ. Impact of ezetimibe on atherosclerosis: is the jury still out? Mayo Clin Proc 2009; 84:353-61.

15. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358:1431-43. http://dx.doi.org/10.1056/NEJMoa0800742

16. Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005; 80:587-95. http://dx.doi.org/10.4065/80.5.587

17. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111:2356-63. http://dx.doi.org/10.1161/01.CIR.0000164260.82417.3F

18. Jayaram S, Jain SD, Bhatia G, et al. Assessment of the efficacy, safety and tolerability of ezetimibe 10mg in adult patients with primary hypercholesterolemia: The first Indian Study. Indian Pract 2004; 57:73-9.

19. Athyros VG, Tziomalos K, Kakafika AI, et al. Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol 2008; 101:483-5. http://dx.doi.org/10.1016/j.amjcard.2007.09.096

20. nFarcas A, Bojita M. Adverse drug reactions in clinical practice: a causality assessment of a case of drug-induced pancreatitis. J Gastrointestin Liver Dis 2009; 18:353-8.

21. Mohan V, Deepa R, Rani SS, Premalatha G, Chennai Urban Population Study (CUPS No.5). Prevalence of coronary artery disease and its relationship to lipids in a selected population in South India: The Chennai Urban Population Study (CUPS No. 5). J Am Coll Cardiol 2001; 38:682-7. http://dx.doi.org/10.1016/S0735-1097(01)01415-2

22. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005; 149:464-73. http://dx.doi.org/10.1016/j.ahj.2004.11.023

23. Piorkowski M, Fischer S, Stellbaum C, et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol 2007; 49:1035-42. http://dx.doi.org/10.1016/j.jacc.2006.10.064

24. Conard S, Bays H, Leiter LA, et al. Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab 2010; 12:210-8. http://dx.doi.org/10.1111/j.1463-1326.2009.01152.x

25. Zieve F, Wenger NK, Ben-Yehuda O, et al. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study). Am J Cardiol 2010; 105:656-63. http://dx.doi.org/10.1016/j.amjcard.2009.10.029

26. Spratt KA. Reducing the risk of coronary heart disease via lipid reduction. J Am Osteopath Assoc 2004; 104:S9-13.

27. Grigore L, Norata GD, Catapano AL. Combination therapy in cholesterol reduction: focus on ezetimibe and statins. Vasc Health Risk Manag 2008; 4:267-78.

28. Mitra S, Deshmukh A, Sachdeva R, Lu J, Mehta JL. Oxidized low-density lipoprotein and atherosclerosis implications in antioxidant therapy. Am J Med Sci 2011; 342:135-42. http://dx.doi.org/10.1097/MAJ.0b013e318224a147

29. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998; 93:229-40. http://dx.doi.org/10.1016/S0092-8674(00)81574-3

30. Nozue T, Michishita I, Mizuguchi I. Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia. J Atheroscler Thromb 2010; 17:37-44. http://dx.doi.org/10.5551/jat.1651

31. Fonseca HA, Izar MC, Bianco HT, Fonseca FA. Ezetimibe, oxidized low density lipoprotein, Lp (a), and dyslipidemia. J Atheroscler Thromb 2010; 17:888. http://dx.doi.org/10.5551/jat.5918

32. Constance C, Westphal S, Chung N, et al. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2007; 9:575-84. http://dx.doi.org/10.1111/j.1463-1326.2007.00725.x

33. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20-8. http://dx.doi.org/10.1056/NEJMoa042378

34. Balk EM, Lau J, Goudas LC, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 2003; 139:670-82.

35. Gupta M, Szmitko PE, Tsigoulis M, et al. Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease. J Cardiovasc Pharmacol 2010; 56:241-5. http://dx.doi.org/10.1097/FJC.0b013e3181e7fd74

36. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107:2409-15. http://dx.doi.org/10.1161/01.CIR.0000068312.21969.C8 PMid:12719279

37. Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol 2007; 49:2003-9. http://dx.doi.org/10.1016/j.jacc.2007.01.083

38. Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation. 2001; 104:1336-42. http://dx.doi.org/10.1161/hc3701.095949

39. Wijnstok NJ, Twisk JW, Young IS, et al. Inflammation markers are associated with cardiovascular diseases risk in adolescents: the Young Hearts project 2000. J Adolesc Health 2010; 47:346-51. http://dx.doi.org/10.1016/j.jadohealth.2010.04.008

40. Rosenson RS, Wolff D, Tangney CC. Statins reduce oxidized low-density lipoprotein levels, but do not alter soluble intercellular cell-adhesion molecule-1 and vascular cell-adhesion molecule-1 levels in subjects with hypercholesterolaemia. Clin Sci (Lond) 2004; 106:215-7. http://dx.doi.org/10.1042/CS20030291

41. Davidson MH, Maccubbin D, Stepanavage M, Strony J, Musliner T. Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol 2006; 97:223-8. http://dx.doi.org/10.1016/j.amjcard.2005.08.038

42. Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract 2008; 62:88-96. http://dx.doi.org/10.1111/j.1742-1241.2007.01592.x

43. Foody JM, Brown WV, Zieve F, et al. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥ 65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study). Am J Cardiol 2010; 106:1255-63. http://dx.doi.org/10.1016/j.amjcard.2010.06.051

44. Denke M, Pearson T, McBride P, et al. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab Vasc Dis Res 2006; 3:93-102. http://dx.doi.org/10.3132/dvdr.2006.020

45. Pearson TA, Denke MA, McBride PE, et al. Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness trial. Mayo Clin Proc 2006; 81:1177-85. http://dx.doi.org/10.4065/81.9.1177